 | |  | |  | |  | |  | |  | |  | |  |
| IJCEM Copyright © 2008-All rights reserved. Published by e-Century Publishing Corporation, Madison, WI 53711 |
Int J Clin Exp Med 2011;4(4):331-340
Original Article
HDFx: A novel biologic immunomodulator is therapeutically-effective in
hemorrhagic and intestinal-ischemic shock: importance of microcirculatory-
immunological interactions and their potential implications for the warfighter and
disaster victims
Burton M Altura, Anthony Carella, Asefa Gebrewold
Department of Physiology and Pharmacology; Department of Medicine; The Center for Cardiovascular & muscle Research; The School
of Graduate Studies Program in Molecular and Cellular Science, State University of New York, Downstate Medical Center, Brooklyn,
New York 11203; 5Bio-Defense Systems, Inc, Rockville Centre, New York 11570
Received October 25, 2011; accepted November 6, 2011; Epub November 9, 2011; Published November 30, 2011
Abstract: Recently, we have reported on the discovery of a new, conserved protein (35-40 kD), termed HDFx, that protects rats, guinea-
pigs, mice and rabbits against lethal hemorrhage, endotoxins, and traumatic injury when given, systemically, as a pretreatment. HDFx
was also found to stimulate several arms of the immune system. The present report demonstrates, for the first time, that HDFx ,when
administered post-hemorrhage and post-intestinal ischemia shock -trauma, yields increased survival rates, elevates falling arterial
blood pressures, possesses unique actions in the microvasculature, stimulates depressed RES phagocytosis (normally observed in
animals and humans during blood loss, sepsis and trauma), and preserves cytokine levels in lymphocytes obtained from animals
subjected to hemorrhage and traumatic shock. We believe that HDFx presents a potential brand new therapeutic approach:1)for the
injured warfighter on the battlefield, 2)for victims of major disasters ,3)as an adjunct for patients undergoing high –risk surgical
procedures commonly found in open-heart surgery, cancers, and in neurosurgeries. Use of HDFx could potentially allow oncologists to
decrease chemotherapy dosing, while increasing patient survival chances. (IJCEM1110008).
Key words: Macrophages, circulatory shock, cytokines, blood pressure, arterioles, venules, phagocytosis, reticuloendothelial system,
vasoactive molecules
Full Text PDF
Address all correspondence to:
Dr. Burton M Altura
SUNY Downstate Medical Center
Box 31, 450 Clarkson Avenue
Brooklyn, NY 11203, USA.
Tel: 718-270-2194; Fax: 718-270-3103
E-mail: baltura@downstate.edu
Original Article
HDFx: A novel biologic immunomodulator is therapeutically-effective in
hemorrhagic and intestinal-ischemic shock: importance of microcirculatory-
immunological interactions and their potential implications for the warfighter and
disaster victims
Burton M Altura, Anthony Carella, Asefa Gebrewold
Department of Physiology and Pharmacology; Department of Medicine; The Center for Cardiovascular & muscle Research; The School
of Graduate Studies Program in Molecular and Cellular Science, State University of New York, Downstate Medical Center, Brooklyn,
New York 11203; 5Bio-Defense Systems, Inc, Rockville Centre, New York 11570
Received October 25, 2011; accepted November 6, 2011; Epub November 9, 2011; Published November 30, 2011
Abstract: Recently, we have reported on the discovery of a new, conserved protein (35-40 kD), termed HDFx, that protects rats, guinea-
pigs, mice and rabbits against lethal hemorrhage, endotoxins, and traumatic injury when given, systemically, as a pretreatment. HDFx
was also found to stimulate several arms of the immune system. The present report demonstrates, for the first time, that HDFx ,when
administered post-hemorrhage and post-intestinal ischemia shock -trauma, yields increased survival rates, elevates falling arterial
blood pressures, possesses unique actions in the microvasculature, stimulates depressed RES phagocytosis (normally observed in
animals and humans during blood loss, sepsis and trauma), and preserves cytokine levels in lymphocytes obtained from animals
subjected to hemorrhage and traumatic shock. We believe that HDFx presents a potential brand new therapeutic approach:1)for the
injured warfighter on the battlefield, 2)for victims of major disasters ,3)as an adjunct for patients undergoing high –risk surgical
procedures commonly found in open-heart surgery, cancers, and in neurosurgeries. Use of HDFx could potentially allow oncologists to
decrease chemotherapy dosing, while increasing patient survival chances. (IJCEM1110008).
Key words: Macrophages, circulatory shock, cytokines, blood pressure, arterioles, venules, phagocytosis, reticuloendothelial system,
vasoactive molecules
Full Text PDF
Address all correspondence to:
Dr. Burton M Altura
SUNY Downstate Medical Center
Box 31, 450 Clarkson Avenue
Brooklyn, NY 11203, USA.
Tel: 718-270-2194; Fax: 718-270-3103
E-mail: baltura@downstate.edu
